Randomized, Open-label, Single Dose, Crossover Phase I Clinical Study to Evaluate the Pharmacokinetics of DW1029M 300 mg, 600 mg and 1200 mg After Oral Administration in Healthy Male Volunteer

Trial Profile

Randomized, Open-label, Single Dose, Crossover Phase I Clinical Study to Evaluate the Pharmacokinetics of DW1029M 300 mg, 600 mg and 1200 mg After Oral Administration in Healthy Male Volunteer

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs DW 1029M (Primary)
  • Indications Diabetic nephropathies
  • Focus Pharmacokinetics
  • Sponsors Dong Wha Pharmaceutical
  • Most Recent Events

    • 16 Jan 2014 New source identified and integrated (Clinical Research Information Service(CriS) - Republic of Korea)
    • 15 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov
    • 18 Dec 2013 Planned End Date changed from 1 Mar 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top